In NOD/SCID mice, CXCR4 inhibitor AMD3465 in combination with G-CSF and protein kinase inhibitor sorafenib improved survival and resulted in reduction of leukemia cells in bone marrow and their absence in spleen or liver (Zeng et al., 2009). This evidence concerns the gene CXCR4 and leukemia.